Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Wenyue Cao; Jia Wei; Na Wang; Hao Xu; Min Xiao; Lifang Huang; Yang Cao; Chunrui Li; Yi Xiao; Chaojiang Gu; Shangkun Zhang; Dengju Li; Yichen Zhang; Tongcun Zhang; Jianfeng Zhou; Liang Huang

doi:10.1182/blood.2020004907

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Blood. 2020 Jul 23;136(4):516-519. doi: 10.1182/blood.2020004907.

Authors

Wenyue Cao^{1

2}, Jia Wei^{1

2}, Na Wang^{1

2}, Hao Xu^{1

2}, Min Xiao^{1

2}, Lifang Huang^{1

2}, Yang Cao^{1

2}, Chunrui Li^{1

2}, Yi Xiao^{1

2}, Chaojiang Gu^{3

4}, Shangkun Zhang⁴, Dengju Li^{1

2}, Yichen Zhang^{1

2}, Tongcun Zhang^{3

4}, Jianfeng Zhou^{1

2}, Liang Huang^{1

2}

Affiliations

¹ Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei China.
² Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
³ College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, Hubei, China; and.
⁴ Wuhan Bio-Raid Biotechnology Co., Ltd., Wuhan, Hubei, China.

PMID: 32291456
DOI: 10.1182/blood.2020004907

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Female
Guanine / administration & dosage
Guanine / analogs & derivatives*
Hepatitis B / etiology
Hepatitis B / prevention & control*
Hepatitis B virus / physiology*
Humans
Immunotherapy, Adoptive / adverse effects*
Male
Middle Aged
Virus Activation / drug effects*

Substances

entecavir
Guanine